Next-Generation Therapeutic Approach
for HRD Tumors
Redefining the treatment of Homologous Recombination Deficiency (HRD) cancers, unlocking new therapeutic pathways and delivering meaningful impact for patients.
About us
At Unguard Therapeutics, we are advancing a new generation of precision oncology by targeting one of cancer’s most exploitable vulnerabilities: Homologous Recombination Deficiency (HRD). Found across multiple tumor types, particularly in female cancers, HRD disrupts DNA repair mechanisms, forcing cancer cells to rely on alternative survival pathways. This dependency creates a powerful opportunity for targeted therapeutic intervention.
Science
More than 2 million cases of breast and ovarian cancer are diagnosed worldwide each year, causing the death of approximately 700,000 women. Over half of these cancers exhibit defects in DNA repair through homologous recombination (HR), most often due to mutations in the BRCA1 or BRCA2 genes.
Our science is built on a differentiated understanding of DNA repair biology and its therapeutic vulnerabilities. We focus on those cancers characterized by homologous recombination deficiency (HRD) where the DNA repair mechanism is impaired and forces tumor cells to rely on alternative pathways for survival.
Join us in redefining precision oncology
Partnering
Partnering with Unguard Therapeutics
Advancing next-generation precision oncology together. We collaborate with pharmaceutical companies, biotech partners, and academic institutions to accelerate the development of innovative therapies targeting HRD cancers.
Our partners
Why partner with us
A differentiated scientific platform
Our approach is built on a novel synthetic lethality mechanism targeting uracil misincorporation and DNA repair vulnerabilities.
Strong scientific foundation
• Institut Curie origin
• validated biological rationale
• robust preclinical data
Partnership opportunities
We are actively exploring:
• Co-development partnerships
• Strategic collaborations in translational research
• Licensing opportunities
• Combination strategies with existing therapies
Areas of interest
• HRD cancers (ovarian, breast, prostate, pancreatic)
• PARPi-resistant populations
• Combination therapies
• DNA repair targeting strategies
Investors
Investment highlights
Market opportunity
Pipeline
Development roadmap
Funding
Get in touch with Unguard Therapeutics
At Unguard Therapeutics we strive to improve and extend the lives of cancer patients without sacrificing their quality of life. We are currently seeking top talent to join our team of experts focused on the development of novel therapies based on synthetic lethality to help us achieve our vision.
We offer a dynamic and fast-paced work environment and value diversity and inclusivity. Different perspectives can only make our team stronger! We are committed to creating a welcoming and supportive work environment for all.
If you’re excited about the opportunity to work on cutting-edge precision oncology discovery, translational, and clinical projects and potentially make a real impact on cancer patients, we would love to hear from you.
General inquiries : contact@unguard-therapeutics.com
Business / partnering: bd@unguardtx.com
Investors relations: investors@unguardtx.com
